RTP Mobile Logo

Amanam I et al. Lower tumor mutational burden (TMB) and hepatic metastases may predict for lack of response to PD-1 blockade in MSI-H metastatic colorectal cancer (MCRC). Proc ESMO 2018;Abstract 535P.

Arnold D et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol 2017;28(8):1713-29. Abstract

Battaglin F et al. Microsatellite instability in colorectal cancer: Overview of its clinical significance and novel perspectives. Clin Adv Hematol Oncol 2018;16(11):735-45. Abstract

Boeckx N et al. The predictive value of primary tumor location in patients with metastatic colorectal cancer: A systematic review. Crit Rev Oncol Hematol 2018;121:1-10. Abstract

Cohen R et al. Assessment of local clinical practice for testing of mismatch repair deficiency in metastatic colorectal cancer: The need for new diagnostic guidelines prior to immunotherapy. Proc ESMO 2018;Abstract 537P.

Cremolini C et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015;16(13):1306-15. Abstract

Das RK et al. Causal modeling of CALGB/SWOG 80405 (Alliance) identifies primary (1°) side-related angiogenic drivers of metastatic colorectal cancer (mCRC). Proc ESMO 2018;Abstract 458PD.

Dienstmann R et al. Molecular subtypes and the evolution of treatment decisions in metastatic colorectal cancer. Am Soc Clin Oncol Educ Book 2018;(38):231-8. Abstract

Heinemann V et al. Somatic DNA mutations, tumor mutational burden (TMB), and MSI status: Association with efficacy in patients (pts) with metastatic colorectal cancer (mCRC) of FIRE-3 (AIO KRK-0306). Proc ASCO 2018;Abstract 3591.

Hoyer L, Schmidt N. Verification of guideline conform mCRC treatment with EGFR inhibitors with real world evidence data from EU5 countries. Proc ESMO 2018;Abstract 489P.

Innocenti F et al. Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome. J Clin Oncol 2019;[Epub ahead of print]. Abstract

Jeong JH et al. HER2 amplification and cetuximab efficacy in patients with metastatic colorectal cancer harboring wild-type RAS and BRAF. Clin Colorectal Cancer 2017;16(3):e147-52. Abstract

Kopetz S et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). Gastrointestinal Cancers Symposium 2017;Abstract 520.

Le DT et al. PD-1 blockade in tumors with mismatch repair deficiency. N Engl J Med 2015;372(26):2509-20. Abstract

Lee JJ, Chu E. Recent advances in the clinical development of immune checkpoint blockade therapy for mismatch repair proficient (pMMR)/non-MSI-H metastatic colorectal cancer. Clin Colorectal Cancer 2018;17(4):258-73. Abstract

Lenz HJ et al. Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). Proc ESMO 2018;Abstract LBA18_PR.

Lenz HJ et al. Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). Proc ASCO 2017;Abstract 3511.

Loree JM et al. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes. Clin Cancer Res 2018;24(5):1062-72. Abstract

Loupakis F et al. Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. Br J Cancer 2018;119(12):1451-5. Abstract

Loupakis F et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst 2015;107(3):dju427. Abstract

Marginean EC, Melosky B. Is there a role for programmed death ligand-1 testing and immunotherapy in colorectal cancer with microsatellite instability? Part I — Colorectal cancer: Microsatellite instability, testing, and clinical implications. Arch Pathol Lab Med 2018;142(1):17-25. Abstract

Marginean EC, Melosky B. Is there a role for programmed death ligand-1 testing and immunotherapy in colorectal cancer with microsatellite instability? Part II — The challenge of programmed death ligand-1 testing and its role in microsatellite instability-high colorectal cancer. Arch Pathol Lab Med 2018;142(1):26-34. Abstract

Morano F et al. Negative hyper-selection of RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients randomized to first-line FOLFOX plus panitumumab (pan) followed by maintenance therapy with either 5FU/LV plus pan or single-agent pan: Translational analyses of the VALENTINO study. Proc ESMO 2018;Abstract LBA22.

Normanno N et al. RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. Ann Oncol 2018;29(1):112-8. Abstract

Ou SI et al. Liquid biopsy to identify actionable genomic alterations. Am Soc Clin Oncol Educ Book 2018;(38):978-97. Abstract

Overman MJ et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 2018;36(8):773-9. Abstract

Overman MJ et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study. Lancet Oncol 2017;18(9):1182-191. Abstract

Parikh A et al. Prolonged response to HER2-directed therapy in a patient with HER2-amplified, rapidly progressive metastatic colorectal cancer. J Natl Compr Canc Netw 2017;15(1):3-8. Abstract

Rich TA et al. RET rearrangements may arise following anti-EGFR therapy in advanced colorectal cancer. Proc ESMO 2018;Abstract 482P.

Ross JS et al. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer 2018;124(7):1358-73. Abstract

Sartore-Bianchi A et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016;17(6):738-46. Abstract

Schirripa M et al. Biomarker-driven and molecular targeted therapies for colorectal cancers. Semin Oncol 2018;45(3):124-32. Abstract

Sclafani F. PD-1 inhibition in metastatic dMMR/MSI-H colorectal cancer. Lancet Oncol 2017;18(9):1141-2. Abstract

Sepulveda AR et al. Molecular biomarkers for the evaluation of colorectal cancer: Guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J Clin Oncol 2017;35(13):1453-86. Abstract

Seufferlein T et al. A novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab: First results of the PERMAD trial. Proc ESMO 2018;Abstract 474P.

Shaikh T et al. Mismatch repair deficiency (dMMR) testing in patients with colorectal cancer and nonadherence to testing guidelines in young adults. JAMA Oncol 2018;4(2):e173580. Abstract

Siena S et al. Final results of the HERACLES trial in HER2-amplified colorectal cancer. Proc AACR 2017;Abstract CT005.

Stintzing S et al. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: Analysis of the FIRE-3 (AIO KRK-0306) study. Eur J Cancer 2017;79:50-60. Abstract

Sunakawa Y et al. Gene mutation status in circulating tumor DNA (ctDNA) and first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) harboring RAS mutation. Proc ESMO 2018;Abstract 543P.

Tejpar S et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: Retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol 2017;3(2):194-201. Abstract

Van Cutsem E et al. BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti-epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer. Proc ESMO World Congress on Gastrointestinal Cancer 2018;Abstract O-027.

Venook AP et al. Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with mCRC: Analysis of CALGB/SWOG 80405 (Alliance). Proc ASCO 2016;Abstract 3504.

Wei XL et al. The clinical and biomarker association of programmed death ligand 1 and its spatial heterogeneous expression in colorectal cancer. J Cancer 2018;9(23):4325-33. Abstract